Claim 1: a Nucleic Acid encoding a Protein of the envelope of Synthetic HIV comprising the amino acid sequence of the SEQ ID No. 8 or SEQ ID No. 8 which has one or more mutationIs selected from the group consisting of (i) i529p k480e, (ii) and (iii) a combination of ek479 - 480rrrr, i529p, a471c and t575c.Claim 9: The vector of claim 8, a viral vector, preferably an adenovirus vector.Claim 13: a combination Vaccine comprising: (i) a First composition comprising an effective amount of a inmunog u00e9nicamente adenovirus vector,Preferably an adenovirus vector 26, which encodes a Protein of the envelope of Synthetic HIV has the amino acid sequence of the SEQ ID No. 8Preferably the SEQ ID no. 18； (ii) a Second composition comprising an effective amount of a Second inmunog u00e9nicamente adenovirus vector,Preferably a Second adenovirus vector 26Encoding a polypeptide Antigen of HIV comprising the amino acid sequence of the SEQ ID no. 5； and (iii) optionally at least one additional composition comprising an amount inmunog u00e9Only effective at least one component selected from the group consisting of (IIIA) a Vector that encodes at least one antigenic polypeptide which has the Amino Acid Sequence SelectionIonada from the group formed by the SEQ ID no. 1 - 4, 28 and 29(IIIB) and a polypeptide comprising an effective amount of a inmunog u00e9nicamente HIV isolated antigenic polypeptide that has 30 708 residues of the amino acid sequence of SEQ ID no.7 or 30 residues - 724 of SEQ ID no. 36, where the first composition,The Second Composition and additional composition are present in the same composition or in one or more different compositions.15: a Vindication of the Synthetic HIV Envelope Protein comprising the amino acid sequence of the SEQ ID No. 8 or SEQ ID No. 8 which has one or more mutations selected fromI529p group consisting of (i), (ii) and (iii) k480e ek479 - a combination of 480rrrr, i529p, a471c and t575c preferably(i) comprising SEQ ID No. 8 is a combination o
